Woolcock researchers are tackling lung infections by focusing on better drug delivery to the lungs. Their work includes:
- Developing advanced medical devices—especially easy‑to‑use, disposable inhalers—that can deliver very small (micron‑sized) antibiotic particles directly to the site of infection, even at the high doses needed for lung disease.
- Creating particle‑science technologies that allow multiple antibiotics to be administered in a single breath, targeting resistant pathogens such as MRSA.
- Conducting clinical studies to understand how patients use inhaled antibiotics and how these treatments can be combined with other medicines.
- Designing solutions for intensive‑care settings, aiming to treat patients on ventilators and to prevent hospital‑acquired lung infections.
These efforts aim to provide more effective, localized treatment for lung infections and reduce the overall burden on the healthcare system.